Publikationen

Anzahl Suchtreffer: 120

1 | 2 | 3 | 4 | 5

Antivirale Strategien

2020

Degen O, Hauber J (2020). Heilung durch Gentherapie? HIV & more. 1; 24-27

Lange UC, Verdikt R, Ait-Ammar A, Van Lint C (2020). Epigenetic crosstalk in chronic infection with HIV-1. Semin Immunopathol. 2020 Feb 11.

2019

Chemnitz J, Pieper D, Stich L, Schumacher U, Balabanov S, Spohn M, Grundhoff A, Steinkasserer A, Hauber J, Zinser E (2019). The acidic protein rich in leucines Anp32b is an immunomodulator of inflammation in mice. Sci Rep. 2019 Mar 19;9(1):4853.

2018

Bialek JK, Walther T, Hauber J, Lange UC (2018). CRISPR-Cas9-based Genome Engineering to Generate Jurkat Reporter Models for HIV-1 Infection with Selected Proviral Integration Sites. J Vis Exp. 2018 Nov 14;(141).

Brunnemann AK, Hoffmann A, Deinhardt-Emmer S, Nagel CH, Rose R, Fickenscher H, Sauerbrei A, Krumbholz A. (2018). Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains. Antiviral Res. 2018 Apr;152:53-57.

Czechowicz JS, Nagel C-H, Voges M, Spohn M, Eibl MM, Hauber J. (2018). Interaction between the cellular E3 ubiquitin ligase SIAH-1 and the viral immediate-early protein ICP0 enables efficient replication of Herpes Simplex Virus type 2 in vivo. PLoS One. 2018 Aug 6;13(8):e0201880.

Hauber I, Beschorner N, Schrödel S, Chemnitz J, Kröger N, Hauber J, Thirion C (2018). Improving Lentiviral Transduction of CD34+ Hematopoietic Stem and Progenitor Cells. Hum Gene Ther Methods. 2018 Apr;29(2):104-113.

Lange UC, Bialek JK, Walther T, Hauber J (2018). Pinpointing recurrent proviral integration sites in new models for latent HIV-1 infection. Virus Res. 2018 Apr 2;249:69-75.

2017

Dunay GA, Solomatina A, Kummer S, Hüfner A, Bialek JK, Eberhard JM, Tolosa E, Hauber J, Schulze zur Wiesch J (2017). Assessment of the HIV-1 Reservoir in CD4+ Regulatory T Cells by a Droplet Digital PCR Based Approach. Virus Res. 2017 Aug 15;240:107-111.

Karpinski J, Schneider M, Lansing F, Hauber J, Buchholz F. (2017). Designer-Rekombinasen für präzises Genome Editing. BIOspektrum. 2017 Mar; 23(2):151–154.

2016

Bialek JK, Dunay GA, Voges M, Schäfer C, Spohn M, Stucka R, Hauber J, Lange UC (2016). Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems. PLoS One. 11:e0158294.

Buchholz F, Hauber J. (2016). Antiviral Therapy of Persitstent Viral Infection Using Genome Editing. Curr Opin Virol. 20:85-91.

Dunay G, Tóth I, Eberhard JM, Degen O, Tolosa E, van Lunzen J, Hauber J, Schulze zur Wiesch J (2016). Parallel Assessment of Th17 Cell Frequencies by Surface Marker Co-Expression Versus Ex Vivo IL-17 Production in HIV-1 Infection. Cytometry B Clin Cytom. 90:486-492.

Gollnest T, Dinis de Oliveira T, Rath A, Hauber I, Schols D, Balzarini J, Meier C. (2016). Membrane-permeable Triphosphate Prodrugs of Nucleoside Analogues. Angew Chem Int Ed Engl. 55:5255-8.

Karpinski J, Hauber I, Chemnitz J, Schäfer C, Paszkowski-Rogacz M, Chakraborty D, Beschorner N, Hofmann-Sieber H, Lange UC, Grundhoff A, Hackmann K, Schrock E, Abi-Ghanem J, Pisabarro MT, Surendranath V, Schambach A, {...} Hauber J, Buchholz F. (2016). Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nat Biotechnol. 34:401-409.

Martinez-Rocha AL, Woriedh M, Chemnitz J, Willinghmann P, Kröger C, Hauber J, Schäfer W. (2016). Posttranslational Hypusination of the Eukaryotic Translation Initiation Factor-5A Regulates Fusarium graminearum Virulence. Scientific Reports 6:4698.

Meinke G, Bohm A, Hauber J, Pisabarro MT, Buchholz F (2016). Cre Recombinase and Other Tyrosine Recombinases. Chem Rev. 2016 Oct 26;116(20):12785-12820.

Mock U, Hauber I, Fehse B. (2016). Digital PCR to Assess Gene-Editing Frequencies (GEF-dPCR) Mediated by Designer Nucleases. Nature Protocols. 11:598-615.

Schröder M, Kolodzik A, Windshügel B, Krepstakies M, Priyadarshini P, Hartjen P, van Lunzen J, Rarey M, Hauber J, Meier C. (2016). Linker-Region Modified Derivatives of the Deoxyhypusine Synthase Inhibitor CNI-1493 Suppress HIV-1 Replication. Arch Pharm (Weinheim) 349, 91-103.

Voges M, Schneider C, Sinn M, Hartig J, Reimer R, Hauber J, Moelling K (2016). Abolishing HIV-1 Infectivity Using a Polypurine Tract-Specific G-Quadruplex-Forming Oligonucleotide. BMC Infect Dis. 16:358.

2015

Geissler R, Hauber I, Funk N, Richter A, Behrens M, Renner I, Chemnitz J, Hofmann-Sieber H, Baum H, van Lunzen J, Boch J, Hauber J, Behrens S-E. (2015). Patient-adapted, Specific Activation of HIV-1 by Customized TAL Effectors (TALEs), a Proof of Principle Study. Virology. 2015 Oct 13;486:248-254.

Han Z, Sakai N, Böttger LH, Klinke S, Hauber J, Trautwein AX, Hilgenfeld R. (2015). Crystal Structure of the Peroxo-diiron(III) Intermediate of Deoxyhypusine Hydroxylase, an Oxygenase Involved in Hypusination. Structure. 2015 May 5;23(5):882-92.

Karimova M, Beschorner N, Dammermann W, Chemnitz J, Indenbirken D, Bockmann J-H, Grundhoff A, Lüth L, Buchholz F, Schulze zur Wiesch J, Hauber J (2015). CRISPR/Cas9 Nickase-Mediated Disruption of Hepatitis B Virus Open Reading Frame S and X. Sci Rep. 2015 Sep 3;5:13734.

Mock U, Machowicz R, Hauber I, Horn S, Abramowski P, Berdien B, Hauber J and Fehse B. (2015). mRNA Transfection of a Novel TAL Effector Nuclease (TALEN) Facilitates Efficient Knockout of HIV Coreceptor CCR5. Nucleic Acids Res. 2015 Jun 23;43(11):5560-71.

Pällmann N, Braig M, Sievert H, Preukschas M, Hermans-Borgmeyer I, Schweizer M, Nagel CH, Neumann M, Wild P, Haralambieva E, Hagel C, Bokemeyer C, Hauber J, Balabanov S (2015). Biological Relevance and Therapeutic Potential of the Hypusine Modification System. J Biol Chem. 2015 Jul 24;290(30):18343-60.

Anzahl Suchtreffer: 120

1 | 2 | 3 | 4 | 5